Resources

Type of publications
Regions
Diseases

5192 results found

2022 ∙ Xiao, Karren Gillissie, Emily S. Lui, Leanna M. W. Ceban, Felicia Teopiz, Kayla M. Gill, Hartej Cao, Bing Ho, Roger Rosenblat, Joshua D. McIntyre, Roger S.

Immune Response to Vaccination in Adults with Mental Disorders: A Systematic Review

  • Adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Gombolay, G. Y. Dutt, M. Tyor, W.

Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Bidari, A. Asgarian, S. Mohammad, A. P. Naderi, D. Anaraki, S. R. Mesgarha, M. G. Naderkhani, M.

Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ ElSawi, H. A. Elborollosy, A.

Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Roy, A. Verma, N. Singh, S. Pradhan, P. Taneja, S. Singh, M.

Immune-mediated liver injury following COVID-19 vaccination: A systematic review

  • Adults
  • COVID-19
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Iheanacho, C. O. Eze, U. I. H.

Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Yin, J. Chen, Y. Li, Y. Wang, C. Zhang, X.

Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Manothummetha, K. Chuleerarux, N. Sanguankeo, A. Kates, O. S. Hirankarn, N. Thongkam, A. Dioverti-Prono, M. V. Torvorapanit, P. Langsiri, N. Worasilchai, N. Moonla, C. Plongla, R. Garneau, W. M. Chindamporn, A. Nissaisorakarn, P. Thaniyavarn, T. Nematollahi, S. Permpalung, N.

Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2022 ∙ Becerril-Gaitan, A. Vaca-Cartagena, B. F. Ferrigno, A. S. Mesa-Chavez, F. Barrientos-Gutierrez, T. Tagliamento, M. Lambertini, M. Villarreal-Garza, C.

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

  • Adults
  • Adolescents
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Uaprasert, N. Pitakkitnukun, P. Tangcheewinsirikul, N. Chiasakul, T. Rojnuckarin, P.

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • Adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...